How should vertebral compression fractures be managed in a patient with a T‑score of –0.5, and is anti‑osteoporotic medication indicated?

Yes, treat with anti-osteoporotic medication—a vertebral compression fracture is itself an indication for pharmacologic therapy regardless of T-score.

A patient with a vertebral compression fracture and a T-score of -0.5 (osteopenic range) should receive anti-osteoporotic pharmacotherapy because the presence of a fragility fracture supersedes BMD criteria and indicates high fracture risk requiring treatment. 1

Why the T-score Doesn't Matter Here

Your patient has already sustained a vertebral compression fracture, which is a sentinel event indicating skeletal fragility 2. The T-score of -0.5 places them in the osteopenic range (between -1.0 and -2.5), but this is irrelevant because:

• Prior vertebral or hip fracture is an absolute indication for treatment regardless of BMD 1
• The majority of osteoporotic fractures actually occur in patients with osteopenic T-scores, not just those with osteoporosis 3
• A vertebral fracture dramatically increases the risk of subsequent fractures, making this a critical intervention point 2

Treatment Algorithm

Immediate Management of the Acute Fracture

1. Conservative management first (unless severe pain refractory to oral medications after 3 months) 4:

   • Analgesics (NSAIDs, judicious narcotics with caution for sedation/fall risk)
   • Early mobilization when tolerated
   • Physical therapy
   • Bracing if needed

2. Consider vertebral augmentation (vertebroplasty or kyphoplasty) if:

   • Pain persists despite 3 months of conservative therapy 4
   • Contraindication to oral medications
   • Requirement for parenteral narcotics
   • Optimal timing: 3-6 weeks after fracture onset 5

Long-term Pharmacologic Therapy (Start Promptly)

Bisphosphonates are first-line for most patients with prior vertebral fracture 6:

• Alendronate or risedronate orally, or zoledronic acid IV annually
• Evidence shows 49% relative risk reduction in vertebral fractures (RR 0.51) 6
• Also reduces hip fracture risk by 33% (RR 0.67) 6

Alternative: Denosumab if bisphosphonates contraindicated 6:

• 68% reduction in vertebral fractures (RR 0.32)
• 40% reduction in hip fractures (RR 0.60)

Essential Adjunctive Measures

• Vitamin D supplementation: minimum 400 IU daily (often 800-1000 IU needed) 1
• Calcium intake: ensure adequate dietary or supplemental calcium per Health Canada recommendations 1
• Fall prevention: balance and resistance training twice weekly 1
• Evaluate for additional vertebral fractures: obtain lateral spine imaging from DXA machine, as two-thirds of vertebral fractures are asymptomatic 7, 2

Critical Pitfalls to Avoid

1. Don't wait for a lower T-score to treat—the fracture itself is the treatment trigger, not the BMD number
2. Don't rely on T-score alone for osteopenia—while isolated osteopenia (T-score -1.0 to -2.5 without fracture) has a high number-needed-to-treat (>100), a fracture changes everything 3
3. Don't forget secondary fracture prevention—without treatment, this patient faces dramatically increased risk of additional vertebral and hip fractures 2
4. Don't overlook malignancy—if clinical presentation is atypical, obtain MRI to exclude pathologic fracture 4, 7

Nuance on Screening vs. Treatment

The 2025 USPSTF guideline 6 addresses screening for osteoporosis in asymptomatic individuals, showing benefit in women ≥65 years. However, your patient is beyond screening—they have a diagnosed fragility fracture, which is a treatment indication independent of screening criteria. The evidence for treating patients with prior vertebral fractures is robust, with clear reductions in subsequent fractures 6.

Bottom line: Initiate bisphosphonate therapy (or denosumab if contraindicated), ensure adequate calcium and vitamin D, implement fall prevention strategies, and manage the acute fracture conservatively unless refractory pain develops after 3 months.